ReviewClinical microbiology reviews2010
Perspectives on clinical and preclinical testing of new tuberculosis vaccines.
Review in Clinical microbiology reviews, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 43 citations in OpenAlex.
- Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis.The New England journal of medicine · 2011Trial
- Understanding the development of tuberculous granulomas: insights into host protection and pathogenesis, a review in humans and animals.Frontiers in immunology · 2024Review
- Review
- Potential Application of Exosomes in Vaccine Development and Delivery.Pharmaceutical research · 2022Review
- B21 DNA vaccine expressing ag85b, rv2029c, and rv1738 confers a robust therapeutic effect against latentFrontiers in immunology · 2022Article
- Neonatal and infant immunity for tuberculosis vaccine development: importance of age-matched animal models.Disease models & mechanisms · 2020Review
- The wide utility of rabbits as models of human diseases.Experimental & molecular medicine · 2018Review
- A New Rabbit-Skin Model to Evaluate Protective Efficacy of Tuberculosis Vaccines.Frontiers in microbiology · 2017Article
- Tuberculosis vaccines and prevention of infection.Microbiology and molecular biology reviews : MMBR · 2014Review
- Crosstalk between Mycobacterium tuberculosis and the host cell.Seminars in immunology · 2014Review
- Immune responses in macaques to a prototype recombinant adenovirus live oral human papillomavirus 16 vaccine.Clinical and vaccine immunology : CVI · 2014Article
- Mast Cells in Lung Homeostasis: Beyond Type I Hypersensitivity.Current respiratory medicine reviews · 2014Article
- Kinetics of IFN-gamma and TNF-alpha gene expression and their relationship with disease progression after infection with Mycobacterium tuberculosis in guinea pigs.Yonsei medical journal · 2013Article
- Article
- CBA/J mice generate protective immunity to soluble Ag85 but fail to respond efficiently to Ag85 during natural Mycobacterium tuberculosis infection.European journal of immunology · 2012Article
- Tuberculosis vaccines in clinical trials.Expert review of vaccines · 2011Review
- A spotlight on liquefaction: evidence from clinical settings and experimental models in tuberculosis.Clinical & developmental immunology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review hopes to improve the selection of new tuberculosis (TB) vaccines by providing several perspectives on the immunization of humans, mice, guinea pigs, rabbits, and monkeys which have not usually been considered. (i) In human TB vaccine trials, the low rate of healing of Mycobacterium bovis BCG lesions (used as the control group) would distinguish individuals who might be helped by vaccination from the 95% who do not need it and would make these trials more conclusive. (ii) The rabbit immune response to Mycobacterium tuberculosis is much more effective in arresting tuberculosis than those of other laboratory animals, so pulmonary tubercle counting in rabbits should be included in all preclinical TB vaccine testing. (iii) Both delayed-type hypersensitivity (DTH) and cell-mediated immunity (CMI) are necessary to control the growth of M. tuberculosis. The testing of new TB vaccines in mice or in guinea pigs may not detect important antigens needed for human immunization. Mice respond poorly to tuberculin-like antigens that cause DTH. Guinea pigs respond poorly to antigens that cause CMI. Rabbits and humans respond well to both DTH and CMI antigens. Since monkeys are very susceptible to M. tuberculosis, they may not be as useful as rabbits for preclinical vaccine evaluation. (iv) Critical antigens (possibly ESAT-6 or CFP-10) might increase the immunity of the host to a greater extent than that produced by a natural M. tuberculosis infection and therefore would be useful in both prophylaxis and immunotherapy. Such critical antigens would increase the host's ability to neutralize key components of M. tuberculosis that enable it to survive in both laboratory animals and humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.